Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Pemetrexed in NSCLC
NCT02182102Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2005
- Primary completion
- May 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 126 days and Incidence and intensity of Adverse Events up to 126 days. Started Sep 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02182102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182102.